SRRKHealthcare · BiotechnologyThe 18 Wall Street analysts covering Scholar Rock Holding Corp. hold a median 12-month price target of $72 — +72.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 24 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Scholar Rock Holding Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (75): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SRRK, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +72.3% from it.
Of the 20 most recent actions, 11 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 Sept 2026 | Truist Securities | Maintains | Buy | $76 → $77 |
| 21 Sept 2026 | JP Morgan | Maintains | Overweight | $63 → $70 |
| 15 Sept 2026 | Barclays | Downgrade | Equal-Weight | — |
| 15 Sept 2026 | Barclays | Downgrade | Equal-Weight | $55 → $58 |
| 15 Sept 2026 | Evercore ISI Group | Maintains | Outperform | $65 → $72 |
| 15 Sept 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 15 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $65 → $70 |
| 15 Sept 2026 | Jefferies | Maintains | Buy | — |
| 15 Sept 2026 | Jefferies | Maintains | Buy | $57 → $65 |
| 15 Sept 2026 | Piper Sandler | Maintains | Overweight | $60 → $75 |
| 15 Sept 2026 | Piper Sandler | Maintains | Overweight | — |
| 15 Sept 2026 | Wedbush | Maintains | Outperform | — |
| 15 Sept 2026 | Wedbush | Maintains | Outperform | $64 → $70 |
| 14 Sept 2026 | BMO Capital | Maintains | Outperform | — |
| 14 Sept 2026 | BMO Capital | Maintains | Outperform | $76 → $84 |
| 14 Sept 2026 | Citigroup | Maintains | Buy | — |
| 14 Sept 2026 | Citigroup | Maintains | Buy | $60 → $74 |
| 14 Sept 2026 | Raymond James | Maintains | Strong Buy | $65 → $72 |
| 14 Sept 2026 | Raymond James | Maintains | Strong Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SRRK appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 23 Oct 2026, Scholar Rock Holding Corp. returned +44.8% against +14.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 95% of US stocks
Cheaper than 5% of US stocks
Cheaper than 87% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 9% of US stocks
Higher than 6% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Scholar Rock Holding Corp. has a market value of $5.1B and an enterprise value of $4.8B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$408.6M.
Diluted earnings per share, trailing twelve months: $−3.45.
Free cash flow in the twelve months to 30 June 2026: −$297.0M.
Trailing P/E: −12.6×; forward P/E: −16.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Scholar Rock Holding Corp. employs 289 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Scholar Rock Holding Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Scholar Rock announced it will report third-quarter 2026 financial results before markets open on November 10, 2026. Management will host a conference call and webcast at 8:00 a.m. ET.
Why it matters — SRRK watchers can note the date and time when the company plans to share its quarterly results and hold a management discussion.
Scholar Rock granted inducement equity awards covering 61,020 shares to seven newly hired employees. The awards include options for 17,461 shares and restricted stock units for 43,559 shares.
Why it matters — The grants are relevant to SRRK watchers as a disclosed equity award tied to the company’s recent hires.
Scholar Rock announced that it has resubmitted its marketing authorisation application for apitegromab to the European Medicines Agency. The application covers treatment of children and adults with spinal muscular atrophy.
Why it matters — The resubmission is a regulatory development for SRRK’s apitegromab program in spinal muscular atrophy.
Scholar Rock announced it granted inducement equity awards covering an aggregate of 83,102 shares of common stock to ten newly hired employees, comprising stock options for 23,801 shares and restricted stock units covering 59,301 shares, under Nasdaq Listing Rule 5635(c)(4).
Why it matters — The grants indicate recent workforce additions and potentially some share dilution, which Scholar Rock watchers may track as they follow the company's hiring and equity plans.
Following FDA approval of ISEMBYLD (apitegromab) for spinal muscular atrophy in patients aged two years and older, Seeking Alpha reiterates a "Strong Buy" rating on Scholar Rock. The article notes expansion potential into younger populations, subcutaneous formulations, and new indications like FSHD, plus planned regulatory filings in Europe and Japan.
Why it matters — The FDA approval and pipeline expansion into new indications and populations represent key growth catalysts that Scholar Rock watchers would track for the company's commercial trajectory.
The 18 Wall Street analysts covering Scholar Rock Holding Corp. have a median 12-month price target of $72, with estimates ranging from $58 to $84. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 18 analysts covering Scholar Rock Holding Corp., 17 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Scholar Rock Holding Corp. 27 out of 100 across roughly 4,600 US stocks as at 24 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 24 Oct 2026, Scholar Rock Holding Corp. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (75 of 100).
No one can know that. What the data says: the median 12-month target from 18 analysts implies +72.3% from the last close, and Ticker Nerd's factor model ranks Scholar Rock Holding Corp. 27 out of 100 as at 24 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Scholar Rock Holding Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SRRK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $58 to $84 over the next 12 months.
Scholar Rock Holding Corp. returned +44.8% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Scholar Rock Holding Corporation Common Stock represents an equity interest in Scholar Rock Holding Corporation, a biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases, with an emphasis on rare neuromuscular disorders such as spinal muscular atrophy (SMA). The company’s current pipeline is centered on apitegromab, its lead investigational therapy, alongside additional programs in neuromuscular and other severe disease areas where protein growth factor signaling plays a key role.
The most recent item we track (Business Wire, 20 Oct 2026): "Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026". Scholar Rock announced it will report third-quarter 2026 financial results before markets open on November 10, 2026. Management will host a conference call and webcast at 8:00 a.m. ET.
Scholar Rock Holding Corporation Common Stock represents an equity interest in Scholar Rock Holding Corporation, a biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases, with an emphasis on rare neuromuscular disorders such as spinal muscular atrophy (SMA). The company’s current pipeline is centered on apitegromab, its lead investigational therapy, alongside additional programs in neuromuscular and other severe disease areas where protein growth factor signaling plays a key role. Scholar Rock applies its myostatin biology platform to advance treatments intended to address significant unmet medical needs in patients across pediatric and adult populations. The company is headquartered in Cambridge, Massachusetts, and its common stock is used by investors to track the market’s view of its clinical development progress, regulatory milestones, and broader biopharmaceutical execution.
CEO Mr. David L. Hallal · 289 employees · United States · https://www.scholarrock.com
